Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals Of The Week: Isis Rethinks Its Partnering Strategy

Executive Summary

Capitalizing on the interest that partners are showing in its beefed-up antisense pipeline, Isis has reset its partnering strategy to maximize the value of each asset. In other developments, Ensemble snagged Novartis in a discovery collaboration and Amgen returned glucokinase activator AMG 151 to Array.

You may also be interested in...



Ensemble Therapeutics Corp.

Ensemble Therapeutics Corp. believes that its large-scale libraries of chemicals with macrocyclic structures will yield worthy drug candidates and ultimately marketable therapeutics. The hefty size of macrocyclic compounds is the key characteristic that Ensemble is banking on. Whereas small molecules generally interact with their targets by binding to them, Ensemble thinks macrocycles will be big enough to spread across the surface of disease-relevant proteins and so physically disrupt interactions that smaller molecules are too weak to influence. If so, macrocycles could hit targets that only protein therapeutics can address now, and potentially do so orally.

Amgen Pays Array $60 Million Upfront For Its Phase One Type 2 Diabetes Compound

The deal for ARRY-403 includes up to $666 million in milestones, a two-year research-funding agreement and U.S. co-promotion option.

Boehringer Ingelheim, Gubra Enter Third Obesity Deal

The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel